Summary
Spirogermanium was given as a 90 minute infusion to 47 eligible patients with refractory Hodgkin's (9 patients) or non-Hodgkin's lymphoma (38 patients). The schedule was 80 mg/m2 three times a week for the first two weeks and 100 mg/m2, 3 times a week, for the two subsequent weeks. In case of response or stable disease, the treatment was continued with biweekly infusions of 100 mg/m2 until tumor progression. In 64% of cases, three or more combinations had been previously administered; 66% of patients presented an extra-lymphatic spread of disease. Two patients with Hodgkin's disease showed a partial response of 11 and 23 weeks and two patients with non-Hodgkin's lymphoma achieved a complete response of 12 and 24 weeks. Overall, 14 patients showed a tumor progression within the first month of treatment. The main toxicity was neurological, with dizziness and lethargy during the infusion in 50% of cases. Hematologic toxicity was almost absent. Spirogermanium is ineffective in heavily pretreated patients with non-Hodgkin's lymphoma. The confirmed lack of activity in patients with refractory malignant lymphoma and the need of repeated and prolonged infusions definitely discourage the clinical use of the drug.
Similar content being viewed by others
References
Slavik M, Blanc O, Davis Y: Spirogermanium: a new investigational drug of novel structure and lack of bone marrow toxicity. Invest New Drugs 1:225–234, 1983
Schein PS, Slavik M, Smythe T, Hoth D, Smith F, Macdonald JS, Woolley PV: Phase I clinical trial of spirogermanium. Cancer Treat Rep 64:1051–1056, 1980
Legha SS, Ajani JA, Bodey GP: Phase I study of spirogermanium given daily. J Clin Oncol 1:331–336, 1983
España P, Kaplan R, Rolichaud K, Gustafson P, Wiernik, Smith F, Woolley P, Schein P: Phase II study of spirogermanium (spiroG) in lymphoma patients. Proc Am Soc Clin Oncol 1:166, 1982 (abstract)
National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. The non-Hodgkin's lymphoma pathologic classification project. Cancer 49:2112–2135, 1982
Lukes RJ, Butler JJ, Hicks ED: Natural history of Hodgkin's disease as related to its pathologic picture. Cancer 19:317–344, 1966
Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47:207–214, 1981
Boros L, Tsiatis AA, Neiman RS, Mann RB, Glick JH: Phase II Eastern Cooperative Oncology Group Study of spirogermanium in previously treated lymphoma. Cancer Treat Rep 70:917–918, 1986
Eisenhauer E, Quirt I, Connors JM, Maroun J, Skillings J: A phase II study of spirogermanium as second line therapy in patients with poor prognosis lymphoma. A NCI Canada Clinical Trials Group Study. Invest New Drugs 3:307–310, 1985
Author information
Authors and Affiliations
Additional information
For the Early Clinical Trials Group of the European Organization for Research Treatment of Cancer (EORTC).
Rights and permissions
About this article
Cite this article
Sessa, C., ten Bokkel Huinik, W., Clavel, M. et al. A phase II study of spirogermanium in patients with advanced malignant lymphoma. Invest New Drugs 7, 219–222 (1989). https://doi.org/10.1007/BF00170861
Issue Date:
DOI: https://doi.org/10.1007/BF00170861